Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 May-Jun;5(3):744-749.
doi: 10.1016/j.jaip.2017.02.018. Epub 2017 Apr 1.

Epidemiology of ACE Inhibitor Angioedema Utilizing a Large Electronic Health Record

Aleena Banerji  1 , Kimberly G Blumenthal  2 , Kenneth H Lai  3 , Li Zhou  4
Affiliations

Epidemiology of ACE Inhibitor Angioedema Utilizing a Large Electronic Health Record

Aleena Banerji et al. J Allergy Clin Immunol Pract. 2017 May-Jun.

Abstract

Background: Angiotensin-converting enzyme inhibitors (ACEIs) are a common cause of drug-induced angioedema in the United States. Most epidemiologic ACEI angioedema data are from large multicenter clinical trials.

Objective: The objective of this study was to identify the incidence of and risk factors for ACEI angioedema using a large integrated electronic health record (EHR).

Methods: We conducted a retrospective cohort study of all ACEI prescriptions in the outpatient setting of a large academic center between January 1, 2000, and September 30, 2008. We determined frequency, timing, and risk factors for ACEI angioedema within 5 years of prescription. All data were derived from EHR sources, with angioedema defined by EHR reactions of angioedema, swelling, edema, or lip, eye, face, tongue, throat or mouth swelling.

Results: Among 134,945 patients prescribed an ACEI, 0.7% (n = 888) developed angioedema during the subsequent 5 years. Sex was similar but patients who developed ACEI angioedema were younger (61.5 vs 62.7 years, P = .007). Patients with ACEI angioedema were more likely to have a history of nonsteroidal anti-inflammatory drug allergy compared with patients who did not develop angioedema (7.1% vs 4.2%, P < .001). We identified a 0.07% incidence of ACEI angioedema within 1 month of prescription and a 0.23% incidence during the first year. Incidence of angioedema was relatively constant annually over the subsequent 4 years (0.10% to 0.12%).

Conclusions: The incidence of ACEI angioedema within a large EHR is consistent with large clinical trial data. We observed a persistent and relatively constant annual risk; however, angioedema risk factors and underlying genetic and pathophysiological mechanisms require further study.

Keywords: Angioedema; Angiotensin-converting enzyme; Drug allergy; Drug hypersensitivity; Electronic health record; Epidemiology.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Timing of reactions to ACE inhibitors documented in EHRs
See this image and copyright information in PMC

References

    1. Ma J, Lee KV, Stafford RS. Changes in antihypertensive prescribing during US outpatient visits for uncomplicated hypertension between 1993 and 2004. Hypertension. 2006;48:846–852. - PubMed
    1. Messerli FH, Nussberger J. Vasopeptidase inhibition and angio-oedema. Lancet. 2000;356:608–609. - PubMed
    1. Kelly M, Donnelly JP, McAnnally JR, Wang HE. National estimates of emergency department visits for angioedema and allergic reactions in the United States. Allergy Asthma Proc. 2013;34:150–154. - PubMed
    1. Banerji A, Clark S, Blanda M, LoVecchio F, Snyder B, Camargo CA., Jr Multicenter study of patients with angiotensin-converting enzyme inhibitor-induced angioedema who present to the emergency department. Ann Allergy Asthma Immunol. 2008;100:327–332. - PubMed
    1. Gabb GM, Ryan P, Wing LM, Hutchinson KA. Epidemiological study of angioedema and ACE inhibitors. Aust N Z J Med. 1996;26:777–782. - PubMed

Substances